Lotan Y - Search Results

1

Epidemiology, Screening, and Prevention of Bladder Cancer.

Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. Lobo N, et al. Among authors: lotan y. Eur Urol Oncol. 2022 Dec;5(6):628-639. doi: 10.1016/j.euo.2022.10.003. Epub 2022 Nov 1. Eur Urol Oncol. 2022. PMID: 36333236 Review.

2

Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.

Lotan Y, Roehrborn CG. Lotan Y, et al. J Urol. 2002 Jan;167(1):75-9. J Urol. 2002. PMID: 11743279

3

Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.

Roehrborn CG, Lotan Y, Tubaro A, de Nunzio C. Roehrborn CG, et al. Among authors: lotan y. Eur Urol. 2006 Feb;49(2):396-400. doi: 10.1016/j.eururo.2005.12.059. Eur Urol. 2006. PMID: 16455190 No abstract available.

4

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Among authors: lotan y. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

5

Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.

Lotan Y. Lotan Y. Eur Urol. 2007 Aug;52(2):453-4. Eur Urol. 2007. PMID: 17674436 No abstract available.

6

Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.

Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Karam JA, et al. Among authors: lotan y. Urology. 2007 Sep;70(3):482-6. doi: 10.1016/j.urology.2007.05.009. Urology. 2007. PMID: 17905101

7

Screening for bladder cancer: a perspective.

Lotan Y, Svatek RS, Malats N. Lotan Y, et al. World J Urol. 2008 Feb;26(1):13-8. doi: 10.1007/s00345-007-0223-2. Epub 2007 Nov 21. World J Urol. 2008. PMID: 18030473 Review.

8

Nomograms for bladder cancer.

Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Shariat SF, et al. Among authors: lotan y. Eur Urol. 2008 Jul;54(1):41-53. doi: 10.1016/j.eururo.2008.01.004. Epub 2008 Jan 15. Eur Urol. 2008. PMID: 18207314 Review.

9

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.

Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Lotan Y, et al. J Urol. 2008 Jun;179(6):2164-9. doi: 10.1016/j.juro.2008.01.105. Epub 2008 Apr 18. J Urol. 2008. PMID: 18423745 Clinical Trial.

10

Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.

Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI. Lotan Y, et al. J Urol. 2009 Jul;182(1):52-7; discussion 58. doi: 10.1016/j.juro.2009.02.142. Epub 2009 May 17. J Urol. 2009. PMID: 19450825

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

743 results

Search Page